Confirmation of these results in alternative drug- or ischemia-induced ALF models (38) as well as in age- and sex-randomized studies is essential for establishing GFAP as a new innovative biomarker for liver injury-related brain parameters. The gene discussed is GFAP; the disease is ischemia.